Phase I study of the selective Aurora A kinase inhibitor MLN8054 in patients with advanced solid tumors: Safety, pharmacokinetics, and pharmacodynamics

Molecular Cancer Therapeutics

Volumn 9, Issue 10, 2010, Pages 2844-2852

  Macarulla, Teresa ^a   Cervantes, Andres ^b   Elez, Elena ^a   Rodríguez Braun, Edith ^b   Baselga, José ^a   Roselló, Susana ^b   Sala, Gemma ^a   Blasco, Inma ^b   Danaee, Hadi ^c   Lee, Yih ^c,d   Ecsedy, Jeffrey ^c   Shinde, Vaishali ^c   Chakravarty, Arijit ^c   Bowman, Douglas ^c   Liu, Hua ^c   Eton, Omar ^c,e   Fingert, Howard ^c   Tabernero, Josep ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c MILLENNIUM PHARMACEUTICALS INC   (United States)

^d FOREST RESEARCH INSTITUTE   (United States)

^e BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [[9 CHLORO 7 (2,6 DIFLUOROPHENYL) 5H PYRIMIDO[5,4 D][2]BENZAZEPIN 2 YL]AMINO]BENZOIC ACID; BENZODIAZEPINE;

ADULT; AGED; ANOREXIA; ARTICLE; ASTHENIA; BEDTIME DOSAGE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INSOMNIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MITOSIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

ADULT; AGED; BENZAZEPINES; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES;

EID: 77958042173     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0299     Document Type: Article

References (20)

1. Katayama H, BrinkleyWR, Sen S. The Aurora kinases: role in cell transformation and tumorigenesis. Cancer Metastasis Rev 2003;22:451-64.
2. Chung CM, Man C, Jin Y, et al. Amplification and overexpression of aurora kinase A (AURKA) in immortalized human ovarian epithelial (HOSE) cells. Mol Carcinog 2005;43:165-74.
3. Yang SB, Zhou XB, Zhu HX, et al. Amplification and overexpression of Aurora-A in esophageal squamous cell carcinoma. Oncol Rep 2007;17:1083-8.
4. Gautschi O, Heighway J, Mack PC, Purnell PR, Lara PN, Jr., Gandara DR. Aurora kinases as anticancer drug targets. Clin Cancer Res 2008;14:1639-48.
5. Nadler Y, Camp RL, Schwartz C, Rimm DL, Kluger HM, Kluger Y. Expression of Aurora A (but not Aurora B) is predictive of survival in breast cancer. Clin Cancer Res 2008;14:4455-62.
6. Landen CN, Jr., Lin YG, Immaneni A, et al. Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. Clin Cancer Res 2007;13:4098-104.
7. Fu J, Bian M, Jiang Q, Zhang C. Roles of Aurora kinases in mitosis and tumorigenesis. Mol Cancer Res 2007;5:1-10.
8. Hoar K, Chakravarty A, Rabino C, et al. MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy. Mol Cell Biol 2007;27:4513-25.
9. Manfredi MG, Ecsedy JA, Meetze KA, et al. Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase. Proc Natl Acad Sci U S A 2007;104:4106-11.
10. Shang X, Burlingame SM, Okcu MF, et al. Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Mol Cancer Ther 2009;8:2461-9.
11. Huck J, Chakravarty A, Yu L, et al. Preclinical PK/PD/efficacy relationship of MLN8054, a small molecule Aurora A kinase inhibitor 2007 (Abstract C191). In: AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2007 Oct 22-26, San Francisco (CA). 2007.
12. Jones SF, Burris HA III, Dumez H, et al. Phase I accelerated dose-escalation, pharmacokinetic (PK) and pharmacodynamic study of PF-03814735, an oral aurora kinase inhibitor, in patients with advanced solid tumors: preliminary results. J Clin Oncol 2008;26:a2517.
13. Dees EC, Infante JR, Cohen RB, et al. Phase I and pharmacokinetic study of MLN8054, a selective inhibitor of Aurora A kinase. Eur J Cancer Suppl 2008;6:91.
14. Lee Y, Eton O, Pappas J, et al. Dosing strategies for MLN8054, a selective Aurora A kinase inhibitor, based on pharmacokinetic modeling and simulations. Eur J Cancer Suppl 2008;6:130-1.
15. Therasse P, Arbuck SG, Eisenhauer EA, et al, European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
16. Chakravarty A, Shinde VB, Galvin K, et al. Phase I assessment of novel mechanistic pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase [abstract]. Eur J Cancer Suppl 2008;6:93.
17. Sells T, Ecsedy J, Stroud S, et al. MLN8237: an orally active small molecule inhibitor of Aurora A kinase in phase I clinical trials. AACR Meeting Abstracts 2008;2008:237.
18. Görgün G, Calabrese E, Hideshima T, et al. A novel aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell cycle arrest in multiple myeloma. Blood 2010;115:5202-13.
19. Infante J, Dees EC, Cohen RB, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MLN8237, a selective Aurora A kinase inhibitor, in the United States. Eur J Cancer Suppl 2008;6:90-1.
20. Tabernero J, Cervantes A, Elez E, et al. MLN8237, an oral selective Aurora A kinase inhibitor: initial results of dose-finding pharmacokinetic- pharmacodynamic phase I study. Eur J Cancer Suppl 2008;6:92.